ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar

Sanofi’s Soliqua combines an insulin with a GLP-1 agonist, and, according to a new real-world study, delivering those two therapies simultaneously is the way to go.

Starting an insulin and a GLP-1 drug around the same time—ideally within 30 days or less of one another—gave certain Type 2 diabetes patients a significantly better shot at achieving blood sugar control than starting them more than three months apart did, according to real-world evidence presented Saturday at the virtual American Diabetes Association annual meeting.